Sarepta Therapeutics, Inc.

As of June 30, 2026, Sarepta Therapeutics, Inc. carries a market capitalization of 1.66B, placing it among publicly traded companies globally. Its enterprise value stands at 1.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sarepta Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Sarepta Therapeutics, Inc. has 105.62M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.95, and the price-to-book ratio stands at 1.24.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.89B versus a market cap of 1.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sarepta Therapeutics, Inc. maintains a current ratio of 4.42, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.45, indicating elevated leverage, while an interest coverage ratio of -1.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sarepta Therapeutics, Inc. posted a negative return on equity (ROE) of -9.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.98, reflecting losses generated across the asset base. The company generates approximately 1.78M in revenue per employee across its workforce of 969.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.85 indicates how many times Sarepta Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sarepta Therapeutics, Inc. recorded 5.08M in income tax expense. The company reported a pretax loss of -114.59M and -119.68M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 6, 2026, Sarepta Therapeutics, Inc.'s stock has declined approximately 21.50% over the past 52 weeks. The 50-day moving average sits at 16.45, while the 200-day moving average is 16.35.

Over the twelve months ended June 30, 2026, Sarepta Therapeutics, Inc. generated 1.73B in revenue and converted that into -119.68M in net income, yielding earnings per share of -1.11. EBITDA reached -86.25M, while operating income came in at -54.48M.

As of June 30, 2026, Sarepta Therapeutics, Inc. holds 690.16M in cash and equivalents against 915.43M in total debt, resulting in a net debt position of 242.00M. Total book value stands at 1.34B, with working capital of 1.51B providing operational flexibility.

Sarepta Therapeutics, Inc. produced 97.17M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.54M in capital expenditures, free cash flow totaled 65.62M - equivalent to 0.63 per share.

Over the twelve months ended June 30, 2026, Sarepta Therapeutics, Inc. posted a gross margin of 59.09, reflecting its pricing power and cost economics. The operating margin of -3.15 and net profit margin of -6.93 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.85, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sarepta Therapeutics, Inc. shareholders.

Sarepta Therapeutics, Inc.'s most recent stock split took place on July 12, 2012 with a 6:1 split ratio.

As of June 30, 2026, Sarepta Therapeutics, Inc. has an Altman Z-Score of -0.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.